Shin JM, et al. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. http://dx.doi.org/10.5056/jnm.2013.19.1.25

Kichul Yoon and Nayoung Kim. J Neurogastroenterol Motil 2021;27:314-25. https://doi.org/10.5056/jnm20208

Young Sun Kim, and Nayoung Kim. J Neurogastroenterol Motil 2018;24:544-58. https://doi.org/10.5056/jnm18082

Yo Han Park, and Nayoung Kim. Journal of Cancer Prevention 2015;20:25-40. http://dx.doi.org/10.15430/JCP.2015.20.1.25

Gastric cancer is associated with high morbidity and mortality worldwide. To reduce the socioeconomic burden related to gastric cancer, it is very important to identify and manage high risk group for gastric cancer. In this review, we describe the general risk factors for gastric cancer and define high risk group for gastric cancer. We discuss strategies for the effective management of patients for the prevention and early detection of gastric cancer. Atrophic gastritis (AG) and intestinal metaplasia (IM) are the most significant risk factors for gastric cancer. Therefore, the accurate selection of individuals with AG and IM may be a key strategy for the prevention and/or early detection of gastric cancer. Although endoscopic evaluation using enhanced technologies such as narrow band imaging-magnification, the serum pepsinogen test, Helicobacter pylori serology, and trefoil factor 3 have been evaluated, a gold standard method to accurately select individuals with AG and IM has not emerged. In terms of managing patients at high risk of gastric cancer, it remains uncertain whether H. pylori eradication reverses and/or prevents the progression of AG and IM. Although endoscopic surveillance in high risk patients is expected to be beneficial, further prospective studies in large populations are needed to determine the optimal surveillance interval.